CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Plecanatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03120520
NCT03120520Phase 2Completed

A Randomized, Double-blind, Placebo-controlled, 3 Dose Level, Parallel Group Study of the Efficacy and Safety of Plecanatide in Adolescents 12 to < 18 Years of Age With Chronic Idiopathic Constipation (CIC)

Bausch Health Americas, Inc.·interventional·Posted Apr 19, 2017·Updated Oct 4, 2019

In Brief

A Phase 2 clinical trial evaluating Plecanatide and Matching placebo for Chronic Idiopathic Constipation. Completed, enrolled 124 participants across 36 sites.

Detailed Summary

This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to \< 18 years diagnosed with Chronic Idiopathic Constipation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 19, 2017
Enrollment StartJan 1, 2017
Primary CompletionSep 7, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.2 years ago

Interventions

Plecanatidedrug

Matching placebodrug